Our model’s performance as evaluated on validation sets reflecting the real-world prevalence of EGFR mutations in lung adenocarcinoma suggests utility as a rule-out screening tool that could provide rapid genomic insights regarding a patient specimen. The gene discussed is EGFR; the disease is lung adenocarcinoma.